18FDG-PET/CT for predicting the outcome in ER+/HER2- breast cancer patients: comparison of clinicopathological parameters and PET image-derived indices including tumor texture analysis

Table 1 Overall characteristics of 143 ER+/HER2- breast cancer patients without distant metastases

	No. of patients (%)
Age in years
mean (SD), median [min, max]	51.4 (11.4), 50 [30; 78]
Histological type
Invasive ductal carcinoma	129 (90%)
Lobular	7 (5%)
Other	7 (5%)
Grade
Grade 1	7 (5%)
Grade 2	91 (64%)
Grade 3	42 (29%)
Grade unknown	3 (2%)
Progesterone receptor expression
Negative	55 (38%)
Positive	88 (62%)
Tumor classification^a
T1	3 (2%)
T2	53 (37%)
T3	56 (39%)
T4	31 (22%)
Lymph node classification^a
N0	58 (40%)
N1	71 (50%)
N2	11 (8%)
N3	3 (2%)
Stage^a
Stage IIA	25 (18%)
Stage IIB	49 (34%)
Stage IIIA	36 (25%)
Stage IIIB	30 (21%)
Stage IIIC	3 (2%)

ER+/HER2- estrogen receptor-positive/human epidermal growth factor receptor 2-negative, SD standard deviation
^aClinical classification and stage after the clinical examination and before ¹⁸F-FDG-PET/CT according to the seventh edition of the AJCC Cancer Staging Manual

ISSN: 1465-542X